FDA May Allow Furberg To Participate In COX-2 Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
No final decision has been made on the drug safety committee member's eligibility for the early 2005 meeting, FDA maintains. Acting Commissioner Crawford backs away from early statements that Furberg would not participate.